- Home
- NMS vs GANX Comparison
NMS vs GANX Comparison
Compare NMS & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMS | GANX |
|---|---|---|
| Founded | 1993 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.1M | 78.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NMS | GANX |
|---|---|---|
| Price | $12.27 | $1.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 13.5K | ★ 628.4K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 4.11% | N/A |
| EPS Growth | N/A | ★ 31.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $55,180.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.07 | $1.41 |
| 52 Week High | $12.49 | $4.34 |
Technical Indicators
Market Signals| Indicator | NMS | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 55.14 | 50.73 |
| Support Level | $11.70 | $1.65 |
| Resistance Level | $12.49 | $2.10 |
| Average True Range (ATR) | 0.18 | 0.13 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 59.46 | 64.42 |
Price Performance
Historical ComparisonAbout NMS Nuveen Minnesota Quality Municipal Income Fund
Nuveen Minnesota Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Minnesota state income taxes and its secondary investment objective is the enhancement of portfolio value.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.